News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Ipsen Biopharmaceuticals, Inc.
NEWS
JOBS
IN THE PRESS
NEWS
Drug Development
Ipsen, Active Biotech AB Plummet As Prostate Cancer Drug Flunks Late-Stage Trial
April 16, 2015
·
2 min read
Business
Ipsen Plants R&D Foothold in U.S. at New Mass. Facility
April 1, 2015
·
3 min read
Job Trends
Allergan Rival Ipsen to Continue U.S. Hiring Spree
March 13, 2015
·
3 min read
Biotech Beach
The Day In Review: Tercica, Inc. And Ipsen Sign Cross-License Deal
July 19, 2006
·
1 min read
Business
Ipsen Joins Pfizer In Breast Cancer Trials
October 19, 2005
·
1 min read
JOBS
Currently, there are no jobs for this company on BioSpace
Browse all jobs
here
Oops!
There was an issue retrieving the jobs list. Please reload the page to view more jobs.
Title
Location
Company Name
Desc
View details
IN THE PRESS
Press Releases
Ipsen to acquire Kartos Therapeutics, expanding hemato-oncology late-stage pipeline
June 29, 2026
·
12 min read
Press Releases
IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2026
June 9, 2026
·
1 min read
Press Releases
Ipsen announces the launch of an Employee Shareholding Plan
June 1, 2026
·
7 min read
Press Releases
New late-breaking data reinforces IQIRVO®’s impact on ALP, fatigue and pruritus in PBC
May 28, 2026
·
10 min read
Press Releases
Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity
May 19, 2026
·
9 min read
Press Releases
Ipsen initiates a new share buy-back program - May 18, 2026
May 18, 2026
·
5 min read
Press Releases
Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction
May 17, 2026
·
8 min read
Press Releases
Ipsen unveils corabotase, a first-in-class recombinant neuroinhibitor, RNI™, at the SCALE Symposium
May 14, 2026
·
7 min read
Press Releases
Annual General Meeting of Ipsen S.A. held on 13 May 2026
May 14, 2026
·
6 min read
Press Releases
Ipsen S.A. – Evolution of the composition of the Board of Directors
May 14, 2026
·
5 min read
